Balbaloglu Hakan, Tasdoven Ilhan, Yorgancioglu Ipek
Department of General Surgery, Bülent Ecevit University School of Medicine, Zonguldak, Turkey.
Arch Med Sci. 2024 Oct 21;20(5):1400-1406. doi: 10.5114/aoms/178334. eCollection 2024.
Over the past 50 years, the rise in obesity has prompted a search for new treatments. Intragastric injections of botulinum toxin A (BT-A), a safer alternative to surgery, show promise in reducing weight and caloric intake by inducing early satiety. This study examines their efficacy for weight loss.
From 2021 to 2023, we conducted a retrospective analysis of patients who underwent intragastric BT-A injections in a general surgery endoscopy unit. The inclusion criteria were being aged 18-65 and having a body mass index (BMI) over 25 kg/m. Patients with specific medical conditions or incomplete records were excluded. We monitored patient weight and BMI values before the procedure and at monthly intervals, with further assessments conducted in the sixth month, including appetite and patient satisfaction.
Our study on 67 patients, predominantly female (82.1%), aged 35.5 ±9.0 years with a mean BMI of 33.5 ±3.3 kg/m², examined BT-A injections' effectiveness. 58.2% received injections in both gastric antrum and fundus regions, showing greater weight loss (mean: 10.7 ±7.0 kg) than those treated in the antrum alone. Side effects occurred in 16.4%, with various symptoms. High dietary compliance (80.6%) correlated with weight loss, especially among those reporting intense satiety. Patient satisfaction positively correlated with weight loss, highlighting treatment efficacy and patient response to dual-region injections.
Our study suggested that intragastric BT-A injections in the antrum and fundus are effective and safe for satiety and weight loss, with few side effects. Individual responses vary, and diet adherence is crucial. More studies are needed to assess the treatment's efficacy in obesity.
在过去50年里，肥胖率的上升促使人们寻找新的治疗方法。胃内注射A型肉毒杆菌毒素（BT-A）是一种比手术更安全的选择，有望通过诱导早期饱腹感来减轻体重和减少热量摄入。本研究考察了其减肥效果。
2021年至2023年，我们对在普通外科内镜室接受胃内BT-A注射的患者进行了回顾性分析。纳入标准为年龄在18至65岁之间且体重指数（BMI）超过25kg/m²。患有特定疾病或记录不完整的患者被排除。我们在手术前和每月监测患者的体重和BMI值，并在第六个月进行进一步评估，包括食欲和患者满意度。
我们对67例患者进行的研究主要为女性（82.1%），年龄35.5±9.0岁，平均BMI为33.5±3.3kg/m²，考察了BT-A注射的有效性。58.2%的患者在胃窦和胃底区域均接受了注射，其体重减轻幅度（平均：10.7±7.0kg）大于仅在胃窦接受治疗的患者。16.4%的患者出现了副作用，症状各异。高饮食依从性（80.6%）与体重减轻相关，尤其是那些报告有强烈饱腹感的患者。患者满意度与体重减轻呈正相关，突出了治疗效果以及患者对双区域注射的反应。
我们的研究表明，胃窦和胃底内注射BT-A对饱腹感和减肥有效且安全，副作用较少。个体反应存在差异，饮食依从性至关重要。需要更多研究来评估该治疗方法对肥胖症的疗效。
